Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathies

6 May 2022

Abstract excerpt

A promising treatment for β-hemoglobinopathies is the de-repression of γ-globin expression leading to increased fetal hemoglobin (HbF) by targeting BCL11A. Here, we aim to improve a lentivirus vector (LV) containing a single BCL11A shmiR (SS) to further increase γ-globin induction. We engineered a novel LV to express two shmiRs simultaneously targeting BCL11A and the γ-globin repressor ZNF410. Erythroid cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Parvovirus B19 Infection Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35526095
DOI: 10.1016/j.ymthe.2022.05.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathiesPMID 35526095Read ↗

Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.Semantic proximity Read ↗

Regulation of the fetal hemoglobin silencing factor BCL11ASemantic proximity Read ↗

Emerging Genetic Therapy for Sickle Cell DiseaseSemantic proximity Read ↗

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell DiseaseSemantic proximity Read ↗

A Review of Gene Therapies for HemoglobinopathiesSemantic proximity Read ↗

The Fetal-to-Adult Hemoglobin Switch — Mechanism and TherapySemantic proximity Read ↗

Targeted Therapeutic Strategies for Fetal Hemoglobin InductionSemantic proximity Read ↗

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read ↗

Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sicklingSemantic proximity Read ↗

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Semantic proximity Read ↗

Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin.Semantic proximity Read ↗

Advances in Gene Therapy for Inherited HaemoglobinopathiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.